<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4487">
  <stage>Registered</stage>
  <submitdate>12/06/2014</submitdate>
  <approvaldate>12/06/2014</approvaldate>
  <nctid>NCT02163759</nctid>
  <trial_identification>
    <studytitle>A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1)</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>2013-004279-11</secondaryid>
    <secondaryid>GA28948</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ulcerative Colitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Adalimumab
Other interventions - Adalimumab Placebo
Treatment: drugs - Etrolizumab
Other interventions - Etrolizumab Placebo

Active Comparator: Adalimumab + Etrolizumab Placebo - Participants will receive adalimumab up to Week 8 and placebo matched to etrolizumab up to Week 14.

Experimental: Etrolizumab + Adalimumab Placebo - Participants will receive etrolizumab up to Week 14 and placebo matched to adalimumab up to Week 8.

Placebo Comparator: Etrolizumab Placebo + Adalimumab Placebo - Participants will receive placebo matched to etrolizumab up to Week 14 and placebo matched to adalimumab up to Week 8.


Treatment: drugs: Adalimumab
Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.

Other interventions: Adalimumab Placebo
Placebo matched to adalimumab will be administered SC at Weeks 0, 2, 4, 6 and 8.

Treatment: drugs: Etrolizumab
Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W).

Other interventions: Etrolizumab Placebo
Placebo matched to etrolizumab will be administered SC Q4W.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of participants with induction of remission compared with placebo as determined by the Mayo Clinic Score (MCS)</outcome>
      <timepoint>Week 10</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with induction of remission compared with adalimumab as determined by the MCS</outcome>
      <timepoint>Week 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with induction of clinical remission as determined by the MCS</outcome>
      <timepoint>Week 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with clinical response as determined by the MCS</outcome>
      <timepoint>Week 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with improvement in endoscopic appearance of the mucosa as determined by the Mayo Endoscopic Subscore</outcome>
      <timepoint>Week 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with endoscopic remission as determined by the Mayo Endoscopic Subscore</outcome>
      <timepoint>Week 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants who Achieve Remission at Week 10 and who Maintained Remission to Week 14 as Determined by MCS</outcome>
      <timepoint>Week 10 and 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with histological remission as determined by the Geboes Histological Subscore</outcome>
      <timepoint>Week 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with remission, among alpha E integrin high participants as determined by the MCS</outcome>
      <timepoint>Week 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to Week 10 in UC bowel movement signs and symptoms, as assessed by UC-Participant-Reported Outcome Signs and Symptoms (PRO/SS)</outcome>
      <timepoint>Baseline, Week 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to Week 10 in UC abdominal symptoms, as assessed by UC-PRO/SS</outcome>
      <timepoint>Baseline, Week 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to Week 10 in health-related Quality of Life (QOL), as assessed by overall Inflammatory Bowel Disease Questionnaire (IBDQ)</outcome>
      <timepoint>Baseline, Week 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of Etrolizumab: Serum Concentration</outcome>
      <timepoint>Pre-dose (0 hour) on Day 1, Week 10 and Week 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Anti-therapeutic Antibodies (ATA) to Etrolizumab</outcome>
      <timepoint>Pre-dose (0 hour) on Day 1, Week 4, Week 10 and Week 14</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of UC established at least 6 months prior to randomization

          -  Moderately to severely active UC as determined by the MCS

          -  Naive to treatment with any anti-TNF therapy

          -  An inadequate response, loss of response, or intolerance to prior corticosteroid
             and/or immunosuppressant treatment

          -  Background UC therapy may include oral 5-aminosalisylate (ASA), oral corticosteroids,
             budesonide multi-matrix system (MMX), probiotics, azathioprine (AZA), 6-mercaptopurine
             (MP), or methotrexate (MTX) if doses have been stable for the 8 weeks immediately
             prior to randomization

          -  Use of highly effective contraception method as defined by the protocol

          -  Have received a colonoscopy within the past year or be willing to undergo a
             colonoscopy in lieu of a flexible sigmoidoscopy at screening</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  A history of or current conditions and diseases affecting the digestive tract, such as
             indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis,
             Crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, stricture
             (stenosis) of the colon, toxic megacolon, or unremoved adenomatous colonic polyps

          -  Prior or planned surgery for UC

          -  Past or present ileostomy or colostomy

          -  Have received non-permitted inflammatory bowel disease (IBD) anti-integrin therapies
             (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol

          -  Congenital or acquired immune deficiency, chronic hepatitis B or C infection, HIV
             positive

          -  Evidence of or treatment for Clostridium difficile within 60 days prior to
             randomization or other intestinal pathogens within 30 days prior to randomization

          -  History of active or latent tuberculosis (TB), recurrent opportunistic infections,
             severe disseminated viral infections and organ transplant

          -  Any major episode of infection requiring hospitalization or treatment with intravenous
             (IV) antibiotics within 8 weeks prior to screening or oral antibiotics within 4 weeks
             prior to screening

          -  Received a live attenuated vaccine within 4 weeks prior to randomization</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>30/11/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>350</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,TAS,VIC,WA</recruitmentstate>
    <hospital>Bankstown-Lidcombe Hospital - Bankstown</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Mater Adult Hospital - Mackay</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Launceston General Hospital; Gastroenterology Research - Launceston</hospital>
    <hospital>Monash Medical Centre-Moorabbin Campus - Clayton</hospital>
    <hospital>Emeritus Research - Malvern East</hospital>
    <hospital>St Frances Xavier Cabrini Hospital - Malvern</hospital>
    <hospital>Royal Melbourne Hospital; Department of Colorectal Medicine and Genetics - Parkville</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <postcode>2200 - Bankstown</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4740 - Mackay</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>7250 - Launceston</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3145 - Malvern East</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6150 - Murdoch</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Autonoma Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>GO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>PR</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RJ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tallinn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tartu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Durango</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Morelia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Veracruz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Olsztyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Sopot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Torun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Leningrad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moskovskaja Oblast</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhny Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Omsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Rostov-on-Don</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ryazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Sochi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Kragujevac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>NIS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Valjevo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Banska Bystrica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Lucenec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Nitra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Presov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Rimavska Sobota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Sahy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Chernivtsi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Ivano-Frankivsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Poltava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Zaporizhzhia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This Phase III, double blind, placebo and active comparator controlled, multicenter study
      will investigate the efficacy and safety of etrolizumab in induction of remission in
      participants with moderately to severely active UC who are na√Øve to TNF inhibitors and
      refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02163759</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Reference Study ID Number: GA28948 www.roche.com/about_roche/roche_worldwide.htm</name>
      <address />
      <phone>888-662-6728 (U.S. and Canada)</phone>
      <fax />
      <email>global.rochegenentechtrials@roche.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>